XENE Xenon Pharmaceuticals Inc

$XENE all programs are intact and this is huge overreaction. PT have been lowered but now XENE is more attractive M&A target. Epilepsy is the main program and now FDA will make positive decision. MDD was and still is an optionality. Scarce, de-risked epilepsy asset with broader mood-disorder optionality and clean strategic fit for neuroscience buyers.

$XENE Xenon Stock Reaction Is Overblown: Analyst BENZINGA 11:14 AM ET 9/18/2026 Xenon Pharmaceuticals Inc. (XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical company announced a voluntary pause on new patient enrollment in its ongoing depression clinical studies following reports of neuropsychiatric adverse events. Positive Data Drives FDA Submission The regulatory filing relies on clinical data from the Phase 2b X-TOLE and the Phase 3 X-TOLE2 studies. Across both clinical trials, treatment with all four evaluated doses of azetukalner demonstrated a statistically significant reduction in monthly seizure frequency from baseline compared to placebo. Precautionary Pause In Psychiatry Trials In a parallel development, Xenon temporarily halted new participant recruitment in ongoing studies for major depressive disorder and bipolar depression. Read Also: Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out The company implemented this voluntary, precautionary measure in consultation with its Data Safety Monitoring Board to analyze observed neuropsychiatric adverse events and evaluate potential dosing modifications. While these adverse events align with azetukalner’s known safety profile and mechanism, researchers did not observe them in the earlier Phase 2 X-NOVA major depressive disorder study. This enrollment pause does not impact any ongoing epilepsy studies. Updated Timeline For X-NOVA2 Recruitment in the X-NOVA2 study reached approximately 80% of its 450-patient target, providing sufficient statistical power to evaluate the HAM-D17 primary endpoint. Xenon plans to complete six-week dosing for currently enrolled participants and unblind the data, shifting expected topline trial results to the first quarter of 2027. See More: Top Momentum Stocks Wall Street Reaction William Blair on Friday wrote that the stock reaction is overblown given similar incidence rates of psychosis have been reported on the label of blockbuster antidepressants like Zoloft and Wellbutrin, but no black box warning has been issued. Analyst Myles Minter also notes that Potiga (ezogabine), a less selective Kv7 potentiator, had a psychosis incidence of around 1% but was still approved as an antiseizure medication with only a segment in the warnings and precautions section of the label on this safety aspect. Analyst Minter further added that the pause naturally raises concerns about azetukalner’s profile in focal onset epilepsy (FOS). However, any read-through should be limited, as psychosis events in FOS were already known as part of the risk/benefit profile in the indication. William Blair notes that the 42.7% placebo-normalized improvement in median monthly seizure frequency reported in X-TOLE2 is a truly remarkable result in a highly refractory population, and that the single pill, no titration, no drug-drug interaction, and daily dose paradigm will truly turn the impressive profile of azetukalner into a blockbuster product in FOS.

$XENE you know the drill... load up here and play for the bounce. It's now lower than BEFORE the fantastic phase 3 data drop.

$XENE Xenon selloff on enrollment pause overdone, says TD Cowen TD Cowen analyst Joseph Thome announced that azetukalner's new drug application has been submitted for focal onset seizures but also a voluntary enrollment pause on the depression trials. The corresponding share selloff is overdone given the potential in focal onset seizures alone, the analyst tells investors in a research note. TD says the adverse events leading the pause are consistent with the known profile of the Kv7 class, were short lasting, and reversible with no long-term sequelae. TD keeps a Buy rating on Xenon.

$XENE Xenon said it has submitted a New Drug Application to the Food and Drug Administration for azetukalner in focal seizures, moving the drug closer to a potential commercial launch in epilepsy. That leaves investors with two very different questions to weigh: how much the psychiatry setback damages azetukalner's broader opportunity and whether the epilepsy program remains intact. Xenon's depression trials hit unexpected safety problem Xenon said azetukalner's side effects were consistent with its known pharmacology and safety profile but had not emerged in its previous Phase 2 depression research. Xenon is currently assessing potential dose changes that may enhance tolerability. Drug: Azetukalner Indications affected: Major depressive disorder and bipolar depression Action: Temporary pause in new enrollment Existing patients: Remain active X-NOVA2 enrollment: About 360 patients Expected data: Q1 2027

$XENE The stock reaction is overblown given similar incidence rates of psychosis have been reported on the label of blockbuster antidepressants like Zoloft and Wellbutrin.

$XENE and some medium $RARE ribeye on deck today? Techs are solid as well. Of course any small movement from administration and the wheels are off. Lots of stuff n things out there. What are we watching today.. hmmmm. What will she like today? Hmmmmm.

$XENE Trade of the day on $XENE - almost $4 per share of profits and 10%+ and made my day! Follow for setups built like this — entry defined, stop defined, no guessing.

$XENE Xenon Pharmaceuticals price target lowered to $55 from $71 at Wedbush Wedbush lowered the firm's price target on Xenon Pharmaceuticals to $55 from $71 and keeps an Outperform rating on the shares. The firm notes the company Xenon disclosed a pause in new patient enrollment for all azetukalner psychiatric studies. The move follows a DSMB review of blinded data that uncovered neuropsychiatric adverse events. The X-NOVA2 study is about 80% enrolled and management plans to read out data in Q1 2027, which will provide an unblinded look at AEs. Management notes X-NOVA2 powering remains roughly 90% to detect a 2.5-point delta on the HAM-D17 primary endpoint. Regardless, Wedbush is removing the azetukalner major depressive disorder credit from its estimates.

$XENE Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird Baird lowered the firm's price target on Xenon Pharmaceuticals to $90 from $97 and keeps an Outperform rating on the shares.

$XENE (NP) Bit of a sketchy PR starts w/ completion of NDA submission in epilepsy Finishes w/ voluntary pause MDD and BPD studies due to neuropsychiatric adverse events (looking at dose modifications to mitigate) At the least, + readthrough to $BHVN (table hits different now)

$XENE Looks like we're at the accumulation level. Flat for a while and then run. I'm long and slightly red, kind of pink so to speak.

$XENE $XENE Update: All eyes are on today's TD Cowen conference at 2:00 PM ET. While recent panic over the trial pause pushed the stock down, the core epilepsy pipeline (NDA submitted) and $1.25B in cash remain fully intact. Will management's transparency today stop the bleeding and shift focus back to fundamentals? What are your thoughts?

$XENE Bearish near-term. A company that managed to turn its own drug approval filing into a 30% crash deserves the market's suspicion, not its sympathy.

$XENE let's hear some price targets on where everyone thinks we close today? I'm guessing over $41

$XENE She hit me on the hip this morning and said, "hey boy, get your recycled beer can money out of the mason jar and check this out"

$XENE If you squint you can see support around 40.25. My entry point for a starter with target 48.

$XENE Prior support at 43 I doubt it goes much below there I think this is a major overrreaction and a long term buying opportunity

#INSIDERS $XENE CEO and CFO bought 45,000 shares combined at a weighted average price of $37.3587 (range $37.316 to $37.38) worth approximately $1.68 mln (transaction date 2026-09-30; Filings: 1, 2). $REX Director sold 50,000 shares at $42.5507 worth approximately $2.13 mln (transaction date 2026-09-30;

$XENE - "XENE down 30.7% on psychiatry trial pause and insider selling; downgrade and unusual volume confirm institutional bearishness." From the Top Tier Newswire AI model. The short position entry is up 7.4% as of right now.